← Therapeutics
Details checkedClinical trial listing onlyCheckedregistry
Siriraj N-acetylcysteine cisplatin otoprotection study
Also known as: Acetyl Cysteine, N-acetylcysteine, NAC, NCT07364747, COA no. SI 655/2024
Institution-led study
Sponsor / Institution
Institution-led study
Program Type
Therapeutic
Modality
Small Molecule
Stage
Phase 2
Status
Active
Target Gene
—
Route / Mode
Intravenous infusion
Confidence
82%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-09
Geography
Thailand
Population
adult, cisplatin-ototoxicity, otoprotection, cancer
Trial IDs
1
Mechanism
Intravenous N-acetylcysteine 150 mg/kg administered 4-6 hours after cisplatin to prevent cisplatin-induced ototoxic sensorineural hearing loss.
Indications
Notes
Corrected from a hospital-as-company generic drug row to a Siriraj-led Phase 2 cisplatin otoprotection study. ClinicalTrials.gov lists the study as recruiting and non-industry sponsored.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, aliases, allCompanies, isIndustrySponsored, stage, status, route, indications...
IDs: NCT07364747, COA no. SI 655/2024
Key Events
Clinical Trials (1)
Data Checks
institution-led-studyactive-recruitingregistry-only-evidence
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2